Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease

Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD

(2018) Yara Nasser et al.   DIGESTIVE DISEASES AND SCIENCES

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

(2018) Geert D’Haens et al.   GASTROENTEROLOGY

Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD

(2018) Sara Lega et al.   INFLAMMATORY BOWEL DISEASES

Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease

(2018) Konstantinos Papamichael et al.   Journal of Crohns & Colitis

Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis

(2018) Amanda Ricciuto et al.   Journal of Crohns & Colitis

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detections of complications

(2018) Christian Maaser et al.   Journal of Crohns & Colitis

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays

(2016) J. Afonso et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis

(2016) E. J. Mao et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?

(2016) Edward L. Barnes et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease

(2016) Clare Moore et al.   Journal of Crohns & Colitis

Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis

(2015) M. J. Rosen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Change in Erythrocyte Mean Corpuscular Volume During Combination Therapy with Azathioprine and Infliximab Is Associated with Mucosal Healing

(2015) Guillaume Bouguen et al.   INFLAMMATORY BOWEL DISEASES

Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD

(2015) Konstantinos Papamichael et al.   INFLAMMATORY BOWEL DISEASES

Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn’s disease

(2015) Sarah O’Donnell et al.   Journal of Crohns & Colitis

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

(2014) Freddy Cornillie et al.   GUT

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

(2012) Martin Bortlik et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT